Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adjuvant gefitinib or icotinib in stage IA lung adenocarcinoma with micropapillary or solid components
ChiCTR2400087186Phase 2Recruiting
- Sponsor
- Weihai Municipal Hospital
- Start
- Jul 2024
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of gefitinib and icotinib in Non-small cell lung cancer adenocarcinoma (NSCLC) (2 arms), sponsored by Weihai Municipal Hospital. Primary endpoint: Disease-free survival. Started Jul 2024; status: recruiting.
02
Drugs
gefitinibicotinib
03
Conditions
Non-small cell lung cancer adenocarcinoma (NSCLC)
Beyond the preview
Go deeper on ChiCTR2400087186.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400087186.